Ser10
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser10  -  TOP1 (human)

Site Information
GDHLHNDsQIEADFR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 465604

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 , 22 ) , phospho-antibody ( 1 , 22 ) , western blotting ( 22 )
Disease tissue studied:
breast cancer ( 1 , 14 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 ) , cervical cancer ( 20 ) , cervical adenocarcinoma ( 20 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , leukemia ( 22 ) , chronic myelogenous leukemia ( 22 ) , lung cancer ( 14 ) , non-small cell lung cancer ( 14 ) , ovarian cancer ( 7 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 10 ) , breast ( 3 ) , BT-20 (breast cell) ( 14 ) , BT-549 (breast cell) ( 14 ) , Calu 6 (pulmonary) ( 14 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 15 ) , Flp-In T-Rex-293 (epithelial) ( 15 ) , GM00130 (B lymphocyte) ( 19 ) , H2009 (pulmonary) ( 14 ) , H2077 (pulmonary) ( 14 ) , H2887 (pulmonary) ( 14 ) , H322M (pulmonary) ( 14 ) , HCC1359 (pulmonary) ( 14 ) , HCC1937 (breast cell) ( 14 ) , HCC2279 (pulmonary) ( 14 ) , HCC366 (pulmonary) ( 14 ) , HCC4006 (pulmonary) ( 14 ) , HCC78 (pulmonary) ( 14 ) , HCC827 (pulmonary) ( 14 ) , HCT15 (intestinal) ( 1 ) , HeLa (cervical) ( 2 , 6 , 13 , 21 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 17 ) , HeLa S3 (cervical) ( 17 , 20 ) , HOP62 (pulmonary) ( 14 ) , HUES-9 ('stem, embryonic') ( 18 ) , Jurkat (T lymphocyte) ( 11 ) , K562 (erythroid) ( 13 , 21 , 22 ) , LCLC-103H (pulmonary) ( 14 ) , MCF-7 (breast cell) ( 14 ) , MDA-MB-231 (breast cell) ( 1 , 14 ) , MDA-MB-468 (breast cell) ( 14 ) , NCI-H1395 (pulmonary) ( 14 ) , NCI-H1568 (pulmonary) ( 14 ) , NCI-H157 (pulmonary) ( 14 ) , NCI-H1648 (pulmonary) ( 14 ) , NCI-H1666 (pulmonary) ( 14 ) , NCI-H2030 (pulmonary) ( 14 ) , NCI-H2172 (pulmonary) ( 14 ) , NCI-H322 (pulmonary) ( 14 ) , NCI-H520 (squamous) ( 14 ) , NCI-H647 (pulmonary) ( 14 ) , ovary ( 7 ) , PANC-1 (pancreatic) [PRP4 (human), knockdown, Lentiviral introduced doxycycline-inducible PRP4 shRNA] ( 9 ) , PANC-1 (pancreatic) ( 9 ) , PC9 (pulmonary) ( 14 ) , SH-SY5Y (neural crest) ( 8 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Regulatory protein:
PRP4 (human) ( 9 ) , PTEN (human) ( 1 )
Kinases, in vitro:
CK2A1 (human) ( 22 , 23 ) , DNAPK (human) ( 1 )
Treatments:
aphidicolin ( 22 ) , EGF ( 2 ) , hydroxyurea ( 22 ) , ionizing_radiation ( 19 ) , nocodazole ( 20 , 22 ) , taxol ( 22 )

Downstream Regulation
Effects of modification on TOP1:
protein degradation ( 1 )

References 

1

Ando K, et al. (2017) Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget 8, 43733-43751
28415827   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

5

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

8

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

9

Gao Q, et al. (2013) Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem 288, 30125-38
24003220   Curated Info

10

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

11

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

12

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

13

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

14

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

15

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

16

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

17

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

18

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

19

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

20

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

21

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

22

Hackbarth JS, et al. (2008) Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I. J Biol Chem 283, 16711-22
18408216   Curated Info

23

Cardellini E, Bramucci M, Gianfranceschi GL, Durban E (1994) Human topoisomerase I is phosphorylated in vitro on its amino terminal domain by protein kinase NII. Biol Chem Hoppe Seyler 375, 255-9
8060534   Curated Info